Home / Market News / $ERAS
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Erasca and Bristol Myers Squibb Partner to Test ERAS-0015 with Navlimetostat in Pancreatic Cancer Trial

Nov 18, 2026, 12:02 AM UTC · Primary ticker $ERAS

Erasca and Bristol Myers Squibb announced a clinical collaboration to test a combination therapy for pancreatic cancer. This partnership could provide a new treatment avenue for RAS-mutant cancers and offers potential upside for both companies if the trial is successful.

Erasca and Bristol Myers Squibb have formed a clinical collaboration to evaluate ERAS-0015 and navlimetostat in a Phase 1/2 trial for MTAP-deleted pancreatic cancer. This is significant as it leverages complementary mechanisms of action to target a difficult-to-treat cancer, potentially expanding both companies' oncology portfolios. For Erasca, this partnership with a major pharmaceutical company like BMS validates its asset and shares development costs, offering a positive long-term outlook if the trial progresses. For Bristol Myers Squibb, it diversifies its pipeline and could lead to a new revenue stream. Short-term, ERAS may see a positive bump due to the validation and partnership news, while BMY's impact might be more muted given its larger market cap. The key opportunity for traders is in ERAS, as successful trial results could significantly re-rate the stock.

$ERAS positive Clinical collaboration for key drug
$BMY positive Expands oncology pipeline
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.